Efficacy and Tolerability of Valproic Acid Once Daily Dosing for Juvenile Myoclonic Epilepsy.
- Author:
Sun Ah CHOI
1
;
Soo Yeon KIM
;
Il Han YOO
;
Hye Won RYU
;
Hunmin KIM
;
Byung Chan LIM
;
Hee HWANG
;
Jong Hee CHAE
;
Jieun CHOI
;
Ki Joong KIM
;
Yong Seung HWANG
Author Information
1. Department of Pediatrics, Seoul National University Children's hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Juvenile myoclonic epilepsy;
Valproic acid extended release;
Effectiveness;
Tolerability
- MeSH:
Compliance;
Humans;
Medical Records;
Myoclonic Epilepsy, Juvenile*;
Patient Compliance;
Retrospective Studies;
Seizures;
Valproic Acid*
- From:
Journal of the Korean Child Neurology Society
2014;22(2):47-51
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study was to evaluate the efficacy and tolerability of extended-release valproic acid once daily dosing in juvenile myoclonic epilepsy (JME). METHODS: Medical records of patients who received valproic acid monotherapy for the treatment of JME were retrospectively reviewed. Their clinical information regarding age, gender, seizure types, underlying neurologic status, dosing regimen, response to treatment, and adverse events related to valproic acid, were analyzed. Seizure control, compliance, and adverse events rates were compared between the group of once daily dosing and the group of twice daily dosing. RESULTS: Twenty one patients (11 boys and 10 girls) were included in the study. Twelve patients were taking valproic acid extended-release once daily and nine patients were taking twice a day. More than 50% decrease in myoclonic seizure was achieved in all the patients in both groups. Generalized tonic-clonic seizure was controlled in all the patients who were taking once daily while 3 patients (36%, 3/8 patients) in twice daily group had breakthrough generalized tonic clonic seizures during the 2 year period of treatment. However, there were no statistically significant differences in seizure control, compliance, and adverse event rates between the two groups. CONCLUSION: This study demonstrated that valproic acid extended-release once daily dosing was as effective and tolerable as twice daily in the treatment of JME. Once daily dosing of valproic acid would be convenient which improve patient compliance and consequently bring better outcome in treatment of JME.
